US2018344742A1PendingUtilityA1

Method for promoting wound healing by administering a compound which binds ldl-receptor-related protein (lrp) ligand binding domain

Assignee: ENZO BIOCHEM INCPriority: Sep 22, 2003Filed: May 9, 2018Published: Dec 6, 2018
Est. expirySep 22, 2023(expired)· nominal 20-yr term from priority
G01N 2800/24A61K 38/00G01N 2333/705A61P 3/10G01N 33/564A61K 31/235A61K 31/535A61K 31/185G01N 33/92G01N 33/5041G01N 33/5011A61K 31/538A61K 31/015A61K 31/192A61K 31/395
68
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention relates to the field of therapeutic methods, compositions and uses thereof, that affect, directly or indirectly, the behavior of LRP receptors. These compositions and methods result in the treatment of inflammatory, immunological and metabolic conditions. More particularly, the methods and compositions of the invention are directed to the identification of small molecules, drugs and/or pharmacological agents that affect the Wnt pathway by affecting normal complex formation among various signaling receptors, the LRP5 and LRP6 receptor, and related ligands.

Claims

exact text as granted — not AI-modified
1 . A method for reducing the level of TNF-α in a human patient, comprising:
 administering to a human patient in an amount effective to reduce the level of TNF-α a compound selected from the group consisting of: 
 
       
         
           
           
               
               
           
         
       
     
     
         2 . The method of  claim 1 , wherein the human patient has Diabetes mellitus. 
     
     
         3 . The method of  claim 1 , wherein the compound is 
       
         
           
           
               
               
           
         
       
     
     
         4 . The method of  claim 3 , wherein the human patient has Diabetes mellitus. 
     
     
         5 . The method of  claim 1 , wherein the compound is 
       
         
           
           
               
               
           
         
       
     
     
         6 . The method of  claim 5 , wherein the human patient has Diabetes mellitus. 
     
     
         7 . The method of  claim 1 , wherein the compound is 
       
         
           
           
               
               
           
         
       
     
     
         8 . The method of  claim 7 , wherein the human patient has Diabetes mellitus.

Join the waitlist — get patent alerts

Track US2018344742A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.